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A b s t r A c t
Optic neuritis is defined as an inflammation of the optic nerve, which is mostly idi-
opathic. However, it can be associated with variable causes: demyelinating lesions, 
autoimmune disorders, infections, compressive, toxic, metabolic and hereditary con-
ditions. It is divided into arteritic, which is commonly seen in temporal arteritis/poly-
myalgia rheumatica and non-arteritic optic neuritis, which is associated with advanced 
age, atherosclerosis, hypertension and hyperlipidemia. Among demyelinating disor-
ders, multiple sclerosis is the most common cause. The term optic neuritis is indicated 
by sub-acute unilateral painful visual loss mostly in a young healthy female and by 
excluding glaucoma. The clinical diagnosis of optic neuritis consists of the classic triad 
of visual loss, periocular pain and dyschromatopsia which requires careful ophthal-
mic, neurologic and systemic examinations to distinguish between typical and atypical 
optic neuritis. In neuromyelitis optica, optic neuritis is initially misdiagnosed as optic 
neuritis in multiple sclerosis or other conditions such as ischemic optic neuritis and 
Leber’s disease. Therefore, differential diagnosis is necessary to make a proper treat-
ment plan. According to Optic Neuritis Treatment Trial, the first line of treatment is 
intravenous methylprednisolone with faster recovery and less chance of recurrence of 
optic neuritis and conversion to multiple sclerosis. 
Apart from optic neuritis of various causes, loss of vision could be due to glaucoma or 
uveitis. Glaucoma is optic nerve damage due to an interruption of the production and/
or abduction of vitreous gel of the eye. Uveitis refers to a group of heterogeneous dis-
eases that share the features of intraocular inflammation, but whose etiologies include 
idiopathic autoimmune disease, infections and masquerade syndromes. Acute retinal 
necrosis and detachment may have a debilitating effect on vision and must be rapidly 
diagnosed and managed. The above-mentioned clinical entities, their etiologies and 
current therapies are briefly discussed in this review.
I N t r O D U c t I O N
The internist is often called upon to render opinion and evaluate patients who present 
with ocular problems and/or systemic diseases with ocular involvement. The internist 
is also the initial physician providing treatment for these conditions, and therefore a 
working knowledge of the eye examination is essential in clinical practice. During this 
initial evaluation, a decision will be made for subsequent referral to an ophthalmologist. 
It is important to determine which patients will need urgent ophthalmology referral 
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to prevent loss of vision, or when it would be safe to initiate 
treatment in the office and defer ophthalmology referral. To 
make this judgment one needs to seek the presence of alarming 
symptoms and signs. If such signs are elicited, then an urgent 
referral to ophthalmology is indicated. An overview of the most 
common ocular problems an internist may encounter will be 
herein presented and discussed (Table 1). 






































CMV = cytomegalovirus; HIV = human immunodeficiency virus; HSV 
= herpes simplex virus; VZV = varicella zoster virus 
O P t I c  N e U r I t I s
Optic neuritis is a clinical entity that presents with eye pain 
and blurred vision. Based on its etiology, it can be divided 
into arteritic, and non-arteritic optic neuritis, compressive, 
demyelinating, toxic, metabolic and hereditary optic neuritis. 
Arteritic optic neuritis is associated with connective tissue 
diseases, whereas non-arteritic is related to atherosclerosis, 
hypertension, diabetes and hyperlipidemia. Compressive optic 
neuritis is due to compression of the optic nerve, e.g. by tumors, 
aneurysms, etc. Toxic optic neuritis is the result of damage to 
the optic nerve by chemical substances like drugs, alcohol and 
cigarette smoking. Metabolic optic neuritis associated with 
diabetes mellitus and hereditary optic neuritis comprises an 
extremely rarely seen entity.1,2
A r t e r I t I c  O P t I c  N e U r I t I s
It is usually seen among patients with temporal (or giant-
cell) arteritis and/or polymyalgia rheumatica, as these two 
entities are closely related conditions, affecting middle-aged 
or older people. Many authorities consider them to be dif-
ferent stages of the same disease.3 Polymyalgia rheumatica is 
an inflammatory condition of unknown cause characterized 
by aching and morning stiffness in the cervical region and 
shoulder and pelvic girdles. It usually responds rapidly to 
low doses of corticosteroids and has a favorable prognosis. 
The onset of giant-cell arteritis is usually insidious, but may 
sometimes be abrupt, with partial or complete loss of vision 
in one or rarely both eyes, as its first manifestation.4 Giant-
cell arteritis presents with fever and fatigue due to anemia in 
about 50% of the patients, whereas temporal lobe headache 
is present in over 2/3 of the patients.5 Among individuals > 
65 years old, giant-cell arteritis is responsible for > 15% of 
cases of fever of unknown origin.6,7 Patients may have jaw 
claudication, proximal myalgia and arthralgia, scalp tenderness, 
headache, fatigue, and a significantly increased erythrocyte 
sedimentation rate and C-reactive protein level. Amaurosis 
fugax is a threatening sign of impending arteritic optic neuritis.6 
As compared to non-arteritic, the vision loss is more severe 
and the optic disc is pale. For diagnosing giant-cell arteritis, 
the American College of Rheumatologists has established 
the following criteria:
 - Age at onset ≥ 50 years old
 - New headache
 - Temporal artery with tenderness in palpation or decreased 
pulsation, unrelated to atherosclerosis
 - Biopsy compatible with giant-cell arteritis
 - Increased ESR ( ≥ 50 mm/h)
If three of the above-mentioned five criteria are fulfilled, 
then the diagnosis of giant-cell arteritis is made.8 Rarely, can 
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arteritic optic neuritis occur in other connective tissue disorders, 
such as sarcoidosis and Wegener’s granulomatosis.
N O N - A r t e r I t I c  O P t I c  N e U r I t I s
It is more common than arteritic neuritis and is associated 
with age, atherosclerosis, hypertension, diabetes mellitus and 
hyperlipidemia. Its main categories are age-related macular 
degeneration (AMD) and diabetic retinopathy (DR) resulting 
in macular edema.
Age-related Macular Degeneration (AMD). Age-related 
macular degeneration is the most common cause of blindness 
in individuals over the age of 55 years in the developed world.9 
Its prevalence is estimated to be 0-2% in those aged 55 to 64 
years and increases to 13% in those older than 85 years.10 The 
disease in its early stages develops slowly and asymptomatically 
over a number of years.11 In this disease, the photoreceptors 
of the macula (the central retina) become damaged and die.12 
AMD results in central vision loss and is responsible for one-
third of all forms of untreatable loss of vision.13 An estimated 9 
million older Americans have some form of AMD, and about 
1.75 million have advanced AMD.14,15 AMD is a disease of the 
elderly, and evidence suggests that 10% of individuals aged 65 
to 74 years and 30% of those aged 75 to 85 years have evidence 
of AMD.16 AMD is a gradual, painless, irreversible process in 
which the patient loses bilateral vision.17
Age is the strongest risk factor for AMD. Apart from age, 
cigarette smoking, with a direct association of the number of 
cigarettes with the risk of developing AMD.18,19 Genetic factors 
are responsible for up to 23% of cases, whereas complement 
factor H is also implicated.20-22
AMD starts with deposits of lipid material that accumulate 
under the retinal pigment epithelium (RPE). These deposits, 
which appear as pale yellow spots on the retina, are called 
drusen.21 With increasing age, the RPE cells, which form the 
blood–retinal barrier, become less efficient and the retina is 
no longer able to receive the proper nutrition. This decline in 
the efficiency of the RPE cells also results in the accumula-
tion of waste products (drusen).21 However, most people with 
evidence of drusen deposits maintain good vision.
Regarding therapeutical measures, laser photocoagula-
tion in AMD and photodynamic therapy with verteporfin 
showed a significant reduction in moderate visual loss among 
patients with classic choroidal neovascularization.23 Inhibitors 
of vascular endothelial growth factor (VEGF) have been used 
with good results, but there are some adverse effects like 
endophthalmitis, injury to the lens and retinal detachment.23 
Stem-cell therapy is now being tested to regenerate damaged 
retinal cells.24
Diabetic retinopathy (Dr). Diabetic retinopathy (DR) is 
characterized by the progressive development of well-defined 
morphological abnormalities in the retinal microvasculature 
that can remain relatively stable, that is non-proliferative DR or 
progress to diabetic macular edema and/or proliferative DR.25,26 
DR is one of the most common complications of diabetes and 
is a leading cause of blindness in people of working age in in-
dustrialized countries.27,28 Approximately 25% of patients with 
Type 1 diabetes may have signs of retinopathy after 5 years of 
diabetes, increasing to 60% after 10 years.29 After 25 years, al-
most all (97%) Type 1 diabetics will develop retinopathy.30 Type 
2 diabetic patients may already have background retinopathy at 
the time of diagnosis and over 60% will develop some form of 
retinopathy after 20 years.31 The number of patients with DR 
was 5.8 million in 2005. However, this number will triple to 
17.7 million in 2050.32 With changes in lifestyle and increases 
in lifespan along with the global prevalence of diabetes, it is 
expected that DR will have a continuously growing impact. 
The progression of DR follows a pattern characteristic of 
ischemic retinopathy.33 In the beginning, vascular alterations 
include changes in blood flow, death of retinal pericytes, base-
ment membrane thickening and subtle increases in vascular 
permeability. As the disease progresses, obvious alterations 
in the vascular structure can be seen upon ophthalmoscopic 
examination. These include non-perfused vessels, microaneu-
rysms, dot/blot hemorrhages, cotton-wool spots, venous beading, 
vascular loops and significant vascular leakage. In many patients, 
the retinopathy progresses to proliferative DR, in which the 
new vessel walls are weak and allow the blood to leak out of the 
vessels, resulting in vitreous hemorrhage and subsequent retinal 
detachment. The mechanisms by which elevated blood glucose 
causes tissue injury and disease progression in the retina are not 
fully understood. However, studies have demonstrated that DR 
is a multifactorial disease involving multiple pathways, including 
aldose reductase pathway, oxidative stress, activation of protein 
kinase C and formation of advanced glycation end products 
(AGEs). These pathways lead to retinal pathological changes 
by causing osmotic vascular damage, inducing cell dysfunction 
and apoptosis through activation of mitogen-activated protein 
kinases (MAPKs) and oxidation of intracellular components, 
inducing production of angiogenic cytokines and breakdown of 
the vascular junction proteins.34-38 One of the major hallmarks 
of DR is increased vascular permeability, which leads to the 
development of retinal hemorrhages and fluid accumulation in 
the macula, which is referred to as diabetic macular edema.39
Since the last two decades there have been significant 
developments in the emerging field of pharmacotherapy of 
DR. The advent of laser photocoagulation three decades 
back, was really useful in limiting vision loss in most of the 
cases and is still considered gold standard therapy for the 
treatment of DR. However, corticosteroids and anti-VEGF 
agents have shown promising results with regard to preven-
tion of neo-vascularisation, but remained limited in use due 
to their short-duration effects. Additionally, none of these 
agents have been able to substitute the remarkable durability 
and effectiveness of pan-retinal photocoagulation.
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Studies have led to the recognition of hyperglycemia, hy-
pertension and dyslipidemia as major risk factors for DR. 
Consequently, tight glycemic control, blood pressure control 
and lipid-lowering therapy have all shown proven benefits in 
reducing the incidence and progression of DR.39-41 Fenofibrate 
has been shown to reduce the frequency of first laser treatment 
for macular edema by 31% and for proliferative retinopathy by 
30%.42 The protein kinase C inhibitor ruboxistaurin mesilate, 
administered orally was effective in halting diabetic macular 
edema and vision loss, but not in preventing progression of 
diabetic retinopathy.43 Laser photocoagulation and vitrectomy 
remain as the two conventional approaches for treating sight-
threatening conditions such as macular edema and proliferative 
DR. Anti-VEGF therapy represents a recent breakthrough as 
clinical trials have demonstrated beneficial effects of VEGF 
blockers (pegaptanib, ranibizumab and bevacizumab) in re-
ducing macular edema and causing neo-vascular regression, 
particularly when combined with laser photocoagulation.44 In 
spite of this progress, DR remains a major clinical challenge and 
the number of patients keeps growing as it is sometimes difficult 
to achieve tight glycemic control throughout the course of the 
disease. Moreover, DR can develop even after tight control is 
initiated due to a phenomenon termed ‘metabolic memory’ in 
which the retinal endothelial cells manifest high-glucose-induced 
biochemical alterations long after the initial insult.45 Laser pho-
tocoagulation and anti-VEGF therapy are not always effective 
and anti-VEGF therapy requires repeated treatment and may 
impair neuronal and vascular survival function.46-48 Thus, there 
is a great need for developing new therapeutic approaches for 
this devastating disease. Vitrase (hyaluronidase ovine) is the 
first and only pure, preservative-free, thimerosal-free, ovine 
hyaluronidase, which is FDA-approved as a spreading agent. 
Intravitreal vitrase has shown efficacy and safety in a Phase 
III clinical trial to investigate its promotion of the clearance 
of vitreous hemorrhage from proliferative DR, although the 
agent is not FDA-approved for this purpose.49,50
c e N t r A l  r e t I N A l  A r t e r y  O c c l U s I O N
Central retinal artery occlusion is usually caused by em-
bolism from atherosclerotic plaques or cardiac thrombi or 
endocarditis of the central retinal artery and produces sudden 
painless blindness or visual field deficit. Immediate treatment 
is warranted as beyond 72 hours of the occlusion, it is very 
unlikely that increased perfusion will improve vision.
c e N t r A l  r e t I N A l  v e I N  O c c l U s I O N
It occurs mainly in elderly patients with diabetes mellitus, 
hypertension, among patients with glaucoma and in cases of 
increased blood viscosity due to other reasons (e.g. Behcet’s 
disease). It manifests as sudden painless loss of vision. In 
patients in whom normal retinal perfusion is re-established 
normalization of vision may recur.
r e t I N A l  D e t A c H M e N t
Retinal necrosis may lead to retinal detachment, which is 
the separation of the neural retinal layer from the underlying 
retinal pigment epithelium layer. It is painless and starts with 
flashes of light, floaters and blurred vision that may progress 
to a curtain falling down. Treatment includes corticosteroids, 
laser, diathermy or cryotherapy, photocoagulation, or intra-
vitreal surgery depending on the location and the extent of 
the detachment.51
D e M y e l I N A t I N G  O P t I c  N e U r I t I s
Demyelinating optic neuritis is an inflammatory process of 
the optic nerve occurring most commonly in the 18-to 45-year-
old age group. It is often idiopathic (50% of cases), but it is 
commonly associated with neuro-inflammatory diseases (e.g., 
multiple sclerosis, neuromyelitis optica). Common present-
ing symptoms include rapidly progressive onset of blurred 
vision, decreased color vision and ocular pain worse with eye 
movement. Patients may also complain of abnormal sensation 
associated with objects moving back and forth (Pulfrich phe-
nomenon) and may have worsening symptoms with an increase 
in body temperature (Uhthoff’s phenomenon). Optic neuritis 
in multiple sclerosis (MS), a demyelinating disease that usu-
ally affects young people (<45 years old), especially women, 
manifests with sudden blurred vision, which deteriorates within 
5 to 8 days, is usually unilateral and characteristically there is 
pain in the eye or around it that gets worse with eye move-
ments. This optic deterioration may become better within a 
six months period. Recurrence of optic neuritis is common.52
Examination of patients with typical demyelinating optic 
neuritis may reveal a relative afferent pupillary defect in uni-
lateral or asymmetric cases, decreased color vision and visual 
field defects. Optic nerve head swelling is seen at the onset of 
symptoms in roughly 33% of patients, with a normal-appearing 
disc in 66% of patients. Magnetic resonance imaging (MRI) 
with contrast and fat suppression is the modality of choice for 
identifying optic nerve inflammation, as well as other inflam-
matory lesions, vascular lesions and tumors. Cerebrospinal 
fluid may also be helpful diagnostically, especially in atypical 
cases or when neuro-inflammatory disease or central nervous 
system infection is suspected.53 Although patients may have 
associated white matter brain lesions with idiopathic disease, 
they are at significantly higher risk for multiple sclerosis if 
there are multiple, ovoid white matter lesions, particularly in 
the region of the corpus callosum. It is estimated that patients 
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who present with optic neuritis and without findings in MRI 
have 16% probability to develop multiple sclerosis within 5 
years, whereas patients who have abnormal MRI findings on 
first episode, consist 50% of all cases and have substantially 
bigger probability of developing multiple sclerosis within 5 to 
10 years.54,55
The Optic Neuritis Treatment Trial demonstrated that 
treatment with intravenous (IV) steroids hastens visual re-
covery, although there is no significant improvement in final 
visual outcome. Treatment with oral steroids, however, may 
increase the risk of recurrence and the risk of progression to 
multiple sclerosis, so it is generally avoided. Treatment typically 
consists of methylprednisolone 1 g/day IV for 3 days followed 
by an oral prednisone tapering.
Neuromyelitis optica (NMO) is an acute inflammatory 
demyelinating disease mainly involving the optic nerves and 
spinal cord. Optic neuritis in NMO and MS are nearly identical 
in their initial presentation. However, demyelinating NMO is 
more violent and devastating than MS, hence its correct di-
agnosis is very important. In more than 85% of patients with 
NMO, attack recurs in the form of optic neuritis, transverse 
myelitis, or both, resulting in around 50% of cases in paralysis 
or blindness within 5 years. Sometimes patients with transverse 
myelitis in the cervical spine experience respiratory failure 
and even death.55,56
t O X I c  O P t I c  N e U r I t I s
Toxins closely associated with optic neuropathy include 
carbon monoxide, ethylene glycol, perchloroethylene, metha-
nol and tobacco. Drugs associated with optic neuropathy are 
ethambutol, clioquinol, isoniazid, amiodarone, linezolid, 
methotrexate, sildenafil, oxymetazoline, and infliximab. Moreo-
ver, various chemotherapeutic agents are identified to cause 
optic atrophy, including vincristine, cisplatin, carboplatin 
and paclitaxel. Nutritional deficiencies such as vitamin B12 
in poor countries have a significant role in the endemic optic 
neuropathy which deteriorates by tobacco use.53,55
H e r e D I t A r y  O P t I c  N e U r I t I s
Leber’s Hereditary Optic Neuropathy involves sub-acute 
and painless visual loss with central scotoma and poor color 
vision with sequential involvement of both eyes over a period 
of weeks to months. This disorder predominantly affects young 
men (80%–90%) and is inherited from maternal mitochondrial 
DNA. Funduscopic examination mainly shows circumpapillary 
telangiectasia, while about 1/3 of patients primarily have a 
normal disc appearance. Fat suppressed orbital MRI usually 
shows enhancement of the optic nerve.55
c O M P r e s s I v e  O P t I c  N e U r I t I s
Compressive optic neuropathies may be caused by sinus 
mucocoeles, arterial aneurysm, tumors, mass lesions, thyroid eye 
disease or other orbital processes. Brain and orbital MRI con-
firms or exclude diagnoses of compressive optic neuropathy.55
G l A U c O M A
Glaucoma is the leading cause of vision loss and irreversible 
blindness worldwide. In most patients with glaucoma, loss of 
vision is insidious and usually painless. However, early detec-
tion and treatment of glaucoma is recognized as beneficial in 
arresting or retarding glaucoma.57 Consequently, guidelines 
have been drawn up to improve the care and outcome of 
patients with glaucoma. Glaucoma is associated with optic 
nerve damage due to an interruption in the production and/
or abduction of vitreous gel of the eye.
U v e I t I s
Uveitis refers to a group of heterogeneous diseases that 
share the features of intraocular inflammation but whose 
etiologies include idiopathic autoimmune disease, infections, 
rheumatologic diseases and masquerade syndromes. Cor-
rect diagnosis with timely and appropriate therapy is the key 
to reducing disease-associated morbidity. The multitude of 
possible causes can create diagnostic challenges, but a suc-
cessful approach includes a targeted history of the illness and 
associated symptoms, detailed ocular evaluation and specific 
laboratory investigations.58
Uveitis can refer to inflammation of one or all three com-
ponents, may also include primary inflammations of the retina 
and vitreous, and is often found in connection with systemic 
disease. The most critical question in evaluating a patient with 
intraocular inflammation is whether the disease can be clas-
sified into a specific, defined syndrome. If the answer is yes, 
then the treatment path is clarified. If the specific syndrome 
is elusive, one must take the appropriate steps to try to define 
the underlying pathophysiology, whether it is autoimmune, 
infectious, neoplastic or other masquerade syndromes, as the 
appropriate treatment for these types of diseases vary widely.59
Proper classification according to guidelines is critical for 
the development of a differential diagnosis for the etiology 
of uveitis in affected patients. The anatomic compartment is 
determined by the primary site of the inflammation: anterior 
(anterior chamber), intermediate (vitreous), posterior (retina 
or choroid) and pan-uveitis (anterior chamber, vitreous and 
retina or choroid). Duration of disease is defined as limited if 
equal to or less than a duration of 3 months, and persistent if 
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greater than a duration of 3 months. The course is defined as 
acute if the onset is sudden and duration is limited, recurrent 
if there are repeated disease episodes with periods equal to or 
greater than 3 months of disease inactivity, and chronic when 
the disease is persistent and relapses within 3 months of no 
therapy. Anterior uveitis is most commonly due to Behcet’s 
disease and viral infections, especially herpes simplex virus 
(HSV), varicella zoster virus (VZV) and cytomegalovirus 
(CMV), sarcoidosis, Lyme disease and syphilis. Posterior uveitis 
causing retinitis and/or choroiditis, can be due to toxoplasmosis, 
CMV, human immunodeficiency virus (HIV), HSV, VZV, 
fungal (Candida), parasitic (toxocariasis, cysticercosis) and 
bacterial infections, sarcoidosis and masquerade forms. These 
masquerade syndromes may include lymphomas, leukemias, 
foreign bodies, amyloidosis, juvenile xanthogranulomas, tuber-
culosis, hepatitis C and Whipple’s disease.60, 61 Pan-uveitis may 
be seen-among others- in Vogt–Koyanagi–Harada disease, a 
systemic inflammatory condition characterized by a pan-uveitis, 
often granulomatous, of sudden onset, which may be associated 
with neurologic, dermatologic and auditory involvement.62, 63
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